BriaCell Therapeutics Publishes Phase 3 Bria-IMT Clinical Study In Metastatic Breast Cancer
Benzinga Newsdesk 10 months ago
News
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce its
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce its Phase 3 Bria-IMT™ clinical trial in metastatic breast cancer has been prominently and independently featured in the Nature Medicine Year In Review's publication, "Eleven clinical trials that will shape medicine in 2026"1, linked here.